Tuberculosis (TB) currently ranks alongside HIV/AIDS as one of the leading causes of global mortality, claiming about 1.4 million lives every year.^[@ref1]^ The spread of multi- and extensively drug-resistant (MDR/XDR) TB is widely regarded as a burgeoning health crisis, placing great strain on limited healthcare resources for only modest treatment outcomes (cure rates of 20--50% following complex therapy for up to 30 months with several more costly and toxic agents).^[@ref1]−[@ref3]^ The recent emergence of programmatically incurable tuberculosis has led to many patients being discharged back into the community, further threatening control efforts.^[@ref4],[@ref5]^ In this context, the conditional approval of two new MDR-TB drugs, delamanid (OPC-67683, **1**; see [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) and bedaquiline (TMC-207, **2**), is a tremendous advance, although access to these and repurposed agents such as linezolid (**3**) remains very limited in many countries.^[@ref4],[@ref6]^ To further address this urgent need, the TB Alliance has been developing shorter acting novel regimens involving the nitroimidazooxazine pretomanid (PA-824, **4**).^[@ref7],[@ref8]^ Initial phase III clinical results for the combination of **2**, **3**, and **4** (Nix-TB) in XDR-TB patients look highly encouraging, with 29 of 31 patients who completed the treatment and 6 month follow-up being cured.^[@ref9]^ Another regimen that combines **2** and **4** with pyrazinamide (**5**) and moxifloxacin (**6**) is also demonstrating excellent bactericidal efficacy against both drug-sensitive- and MDR-TB.^[@ref10]^
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The mechanism of action of **4** involves bioreductive activation by a deazaflavin (F420)-dependent nitroreductase (Ddn), leading to several metabolites arising from reduction of the imidazole ring at C-3, including a des-nitro derivative.^[@ref11]^ Formation of the latter correlates with the release of nitric oxide, a crucial element in the *anaerobic* bactericidal activity of **4**, which is considered important for treatment shortening.^[@ref12]^ In contrast, the aerobic killing effects of **4** are attributed to the inhibition of cell wall mycolic acid biosynthesis.^[@ref13]^ The 5-nitroimidazole metronidazole also has some antitubercular activity under hypoxic conditions (*vide infra*), but a clinical study in MDR-TB patients showed that it was too neurotoxic for long-term use.^[@ref14]^

In the past decade, several structure--activity relationship (SAR) studies of the nitroimidazooxazine class have been reported by ourselves and others,^[@ref15],[@ref16]^ seeking more effective second-generation analogues of **4**. While the predominant focus has centered on optimizing the aryl side chain (e.g., clinical candidate TBA-354^[@ref17]^), a few studies examined alternative linkages at C-6^[@ref18]^ or more fundamental modifications to the nitroheterobicyclic "warhead".^[@ref19],[@ref20]^ Here, replacement of the nitroimidazole portion by nitrotriazole or nitropyrazole abolished activity, whereas the 8-oxygen could be exchanged for sulfur or nitrogen, and substitution at C-7 was tolerated.^[@ref21]^ Notably, Kim et al.^[@ref22]^ also described the synthesis and biological evaluation of the 3-nitro isomer of **4**, which was recorded as being "only slightly less active" (5- to 10-fold) than **4** itself, whereas its precursor alcohol derivative was 16- to 31-fold less active than **4**. Furthermore, the anaerobic killing of mutant *Mycobacterium tuberculosis* (*M. tb*) by this isomeric compound was suggested to imply a different biological target. This result could be of particular significance in the event of future clinical resistance to **4**. Nevertheless, in the related nitroimidazooxazole class (cf. **1**), we discovered that relocating the nitro group from C6 to C5 reduced the aerobic MIC against *M. tb* by at least 2--3 orders of magnitude.^[@ref23]^

During initial attempts to optimize a large-scale synthesis of **4**, two trace byproducts were isolated (\<0.5%), and one of these was postulated to be the 3-nitro isomer, although its nuclear magnetic resonance (NMR) data did not match that provided by Kim et al.^[@ref22]^ To establish its identity, we sought to make this 3-nitroimidazooxazine analogue of **4** via an unambiguous chiral synthesis. Concurrently, we also targeted the second compound, thought to be a 3′-methyl derivative of **4**. We now report the intriguing findings from this study, including some preliminary biological assessments.

To prepare the 3-nitro isomer of **4**, we first investigated the method of Kim^[@ref22]^ ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}A). Reaction of 2-chloro-4-nitroimidazole (**10**) with the TBS ether derivative of *R*-glycidol (**11**) gave two products in a ratio of ∼3:1, with the major one being the expected 4-nitroimidazole derivative **12**, as described. However, after low-temperature crystallization of the more polar oily minor product (reportedly the 5-nitroimidazole isomer of **12**, i.e., **13**), we found that its ^1^H NMR spectrum in CDCl~3~ contained a D~2~O-exchangeable hydroxyl proton resonance at δ~H~ 1.83 ppm, which appeared as a sharp "dd" (*J* = 6.7, 5.1 Hz), and coupled to the two proton resonance of a methylene group in a COSY experiment. Moreover, a NOESY experiment revealed a strong NOE effect between the imidazole proton resonance and the proton resonances from the directly attached *N*-methylene. HMBC correlations between H-5 and this NCH~2~ carbon and between the NCH~2~ protons and both C-2 and C-5 ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}) confirmed that the correct structure of this minor product was the 4-nitroimidazole **16**. This result is in good accordance with the known tendency of a TBS group to migrate under basic conditions, as employed here.^[@ref24]^

![Two-dimensional NMR evidence for structure **16** over the reported **13**.](ml-2017-003562_0002){#fig2}

![Synthesis of the Target Compounds **7**--**9**, Highlighting a Key Nitration Step\
Reagents and conditions: (i) K~2~CO~3~, EtOH, 70 °C, 20 h (for **12**/**16**), or 75--82 °C, 23 h (for **23**); (ii) 3,4-dihydro-2*H*-pyran, PPTS, toluene, 20 °C, 5 d; (iii) TBAF, THF, 124 °C, 24 h (sealed tube); (iv) conc. HCl (1.1 equiv), MeOH, 20 °C, 15 h; (v) AcCl, pyridine, 0--20 °C, 4 h; (vi) Ac~2~O, pyridine, 0--20 °C, 7--19 h; (vii) TFAA, −5 to 0 °C, 15 min, then conc. HNO~3~, −50 to 20 °C, 3 h, then ice, NaHCO~3~; (viii) Ac~2~O, 0--20 °C, 5--80 min, then conc. HNO~3~, conc. H~2~SO~4~, −50 to 0 °C, 1.5--2.5 h, then ice, NaHCO~3~; (ix) NaHCO~3~, aq. MeOH, 20 °C, 5 h; (x) 4-OCF~3~BnBr or **37**, NaH, DMF, 0--20 °C, 2.5--3.3 h; (xi) *n*BuLi, THF, −78 °C, 1 h, then DMF, −78 to 20 °C, 1.5 h, and then aq. citric acid; (xii) NaBH~4~, MeOH, 0--20 °C, 1.5 h; (xiii) HBr, AcOH, 20 °C, 13 h.](ml-2017-003562_0004){#sch1}

A critical consequence of this structural assignment error is that subsequent THP protection of the primary hydroxyl of **16** and treatment with TBAF (as reported) would induce cyclization to a 6-nitroimidazooxazole (**18**), rather than the 3-nitroimidazooxazine **15** ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}A). Therefore, following THP deprotection and installation of the 4-(trifluoromethoxy)benzyl ether, Kim et al. finally obtained **20** (instead of **8**), equivalent to the 2*S* enantiomer of compound **10** in our nitroimidazooxazole paper,^[@ref23]^ as verified by their identical ^1^H and ^13^C NMR data. We note that while our compound had been prepared by an independent and unequivocal method, we have rigorously confirmed its structure by 2D NMR, including a NOESY experiment, where an NOE effect was observed between the imidazole proton resonance (H-5) and resonances from the adjacent methylene protons at the 3-position in the oxazole ring. This revised structure (**20**) for the compound claimed by Kim et al. as **8** is also consistent with the much smaller than expected optical rotation value obtained (\[α\]~D~^20^ +7.4; cf. −44.7 for **4** in MeOH^[@ref25]^) as well as the moderate antitubercular potency recorded (*vide infra*), as *S* enantiomers are known to be an order of magnitude less effective than *R* forms in the 2*H*-nitroimidazooxazole class.^[@ref23]^

In an alternative approach to the 3-nitro isomer of **4**, we explored the novel nitration of known^[@ref22]^ imidazooxazine alcohol **26** ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}B). This strategy was based on previous success in our laboratory with the nitration of a related 5,6,7,8-tetrahydroimidazo\[1,2-*a*\]pyridin-6-ol in acetic anhydride,^[@ref19]^ as well as literature precedence for the regioselective C-5 nitration of both 1-methyl-2-(methylsulfanyl)-1*H*-imidazole^[@ref26]^ and 2,3-dihydroimidazo\[2,1-*b*\]\[1,3\]thiazole.^[@ref27]^ During our initial synthesis of **26**, we again encountered a problem with migration of the TBS group when glycidyl ether **11** was reacted with 2-nitroimidazole (**21**).^[@ref22]^ Fortunately, this was easily overcome by switching the protecting group to the more stable TIPS (**22**).^[@ref24],[@ref25]^ We also made improvements to the subsequent THP protection and deprotection steps by adopting methods from Orita et al.,^[@ref25]^ enabling the synthesis of alcohol **26** in 65% yield over four steps. Surprisingly, attempted preparation of its acetate ester (**30**) using acetyl chloride in pyridine gave only ring opened *N*-acetyl imidazol-2-one products, **27** and **28** (having a distinctive ^1^H NMR methyl resonance^[@ref28]^ at δ~H~ 2.64 ppm); this was largely circumvented by employing acetic anhydride.

Several reagent systems were then explored for the nitration of **26** or **30** ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). Neither heating in aqueous nitric acid nor treatment with acetyl nitrate in acetic anhydride gave the desired product, while a reaction of **30** with nitronium tetrafluoroborate was low-yielding and accompanied by minor side products. Overall, the best conditions were 70% nitric acid in trifluoroacetic anhydride^[@ref29]^ or a mixture of concentrated nitric and sulfuric acids in acetic anhydride, which enabled yields of ∼25--30% of the 3-nitro derivatives, **7** and **33**, respectively. Intriguingly, only one nitro isomer was formed in trifluoroacetic anhydride, but this reaction proved to be more capricious than the acetic anhydride alternative, where the isomer ratio was ∼9:1 in favor of nitration at C-3 over C-2 (for confirmation, known^[@ref25]^ 2-nitro acetate ester **32** was prepared from alcohol **31**([@ref30])). Isomers **32** and **33** were separable by careful column chromatography, and cleavage of acetate **33** to alcohol **7** was cleanly achieved through the use of a mild base (NaHCO~3~).

###### Summary of Nitration Methods Explored for the Synthesis of Alcohol **7** or Acetate **33**

  compd                                    solvent   reagents (equiv)                                   temp range (°C)   time/temp        products (% yield)
  ---------------------------------------- --------- -------------------------------------------------- ----------------- ---------------- ----------------------------------------------------------------------
  **26**                                   H~2~O     3 M HNO~3~ (9)                                     80 to 97          3 h/97 °C         
  **26**                                   H~2~O     50% HNO~3~ (\>100)                                 90                2 h/90 °C         
  **26**[a](#t1fn1){ref-type="table-fn"}   Ac~2~O    70% HNO~3~ (3.1)[b](#t1fn2){ref-type="table-fn"}   --15 to 20        16 h/20 °C        
  **26**[a](#t1fn1){ref-type="table-fn"}   Ac~2~O    96% H~2~SO~4~ (1.7), 100% HNO~3~ (3.0)             --55 to 0         60 min/0 °C      **32** (\<3), **33** (20)[c](#t1fn3){ref-type="table-fn"}
  **26**[a](#t1fn1){ref-type="table-fn"}   Ac~2~O    96% H~2~SO~4~ (1.7), 70% HNO~3~ (3.0)              --50 to 0         75 min/0 °C      **32** (\<3), **33** (26)[c](#t1fn3){ref-type="table-fn"}
  **26**[a](#t1fn1){ref-type="table-fn"}   Ac~2~O    96% H~2~SO~4~ (2.5), KNO~3~ (1.7)                  --35 to −30       20 min/--30 °C   **32** (\<2), **33** (14)[c](#t1fn3){ref-type="table-fn"}
  **26**[a](#t1fn1){ref-type="table-fn"}   TFAA      70% HNO~3~ (2.5--2.8)                              --50 to 20        2--3 h/20 °C     **7** (12--35)
  **30**                                   CH~3~CN   NO~2~BF~4~ (1.5)                                   --48 to 20        90 min/20 °C     **30** (15), **32** (1), **33** (14)[c](#t1fn3){ref-type="table-fn"}
  **30**                                   Ac~2~O    96% H~2~SO~4~ (1.9), 70% HNO~3~ (3.2)              --50 to 0         30 min/0 °C      **32** (\<3), **33** (28)[c](#t1fn3){ref-type="table-fn"}

Acetylated or trifluoroacetylated in situ, prior to nitration.

Preformed acetyl nitrate.

Yields after chromatography and crystallization.

Importantly, all of the successful nitration methods gave a complete retention of stereochemistry (100% ee by chiral HPLC analysis, using the analogously synthesized racemic form of **7** as a reference standard). This indicated that the in situ formed trifluoroacetate or acetate esters were sufficiently stable to protect the chiral alcohol from potential racemization, e.g., through the formation of a chiral nitrate ester and subsequent hydrolysis, as this can induce inversion of configuration.^[@ref31]^ Alkylation of pure **7** with 4-(trifluoromethoxy)benzyl bromide (NaH/DMF) then gave the desired target **8** in excellent yield (95%), and gratifyingly, this proved to be identical (by NMR, mp, HPLC, and optical rotation) to the first byproduct derived from optimization studies for a large-scale process route to **4**. As expected from findings in the nitroimidazooxazole class, the rotation value for **8** {\[α\]~D~^24^ −150.7 (*c* 1.002, CHCl~3~)} was indeed much larger than the one recorded for **4**.^[@ref25]^ Conclusive structural proof was gained through a single-crystal X-ray structure ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}); of note, the benzyloxy side chain adopted a pronounced pseudoaxial conformation at C6, the same as that observed in the previously reported crystal structure of **4**.^[@ref21]^

![X-ray crystal structure of compound **8**.](ml-2017-003562_0003){#fig3}

Preparation of the second byproduct from the synthesis of **4** was straightforward ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}C). Lithiation of bromotoluene **34** and quenching with DMF gave the required aldehyde **35**, which was easily reduced (NaBH~4~) and brominated to give **37**. Alkylation of chiral alcohol **31**([@ref30]) with bromide **37** then provided the expected compound **9**, which was also identical to that derived from the nonoptimized process chemistry route for **4**. This byproduct (\<0.2%) was postulated to arise from traces of **37** in the bulk commercial 4-(trifluoromethoxy)benzyl bromide. Full experimental procedures and characterization data for all compounds have been provided in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.7b00356/suppl_file/ml7b00356_si_001.pdf).

The comparative effects of **7**--**9** and several reference drugs against *M. tb* (strain H37Rv) were assessed in two *in vitro* assays, MABA^[@ref32]^ and LORA,^[@ref33]^ conducted under aerobic and hypoxic conditions, respectively. The latter assay employed bacteria preadapted to low oxygen conditions and represented a targeted screen for the identification of agents with better sterilizing ability against nonreplicating persistent bacteria. Recorded minimum inhibitory concentrations (MICs) corresponding to growth inhibitions of ≥90% ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}) were mean values obtained from replicate measurements (± standard deviation). Compounds **7**--**9** were also evaluated for cytotoxicity against mammalian cells (VERO) in a 72 h assay^[@ref32]^ and found to be nontoxic (IC~50~ \> 128 μM).

###### *In Vitro* Activities of **7**--**9** versus Other TB Drugs

                                          MIC[a](#t2fn1){ref-type="table-fn"} (μM)                 
  --------------------------------------- ------------------------------------------ ------------- -------
  **2**                                   0.070 ± 0.018                              0.11 ± 0.03   \>10
  **3**                                   2.9 ± 1.2                                  2.8 ± 0.3      
  **4**[c](#t2fn3){ref-type="table-fn"}   0.50 ± 0.30                                2.6 ± 1.4     \>128
  **6**                                   0.42 ± 0.13                                \>128          
  **7**                                   \>128                                      \>128         \>128
  **8**                                   \>128                                      \>128         \>128
  **9**                                   0.063 ± 0.003                              1.0 ± 0.1     \>128
  MET                                     \>512                                      79 ± 40        
  RMP                                     0.049 ± 0.027                              0.64 ± 0.35   \>100
  INH                                     0.34 ± 0.18                                \>128          

Minimum inhibitory concentration against *M. tb*, determined under aerobic (MABA)^[@ref32]^ or hypoxic (LORA)^[@ref33]^ conditions. Each value is the mean of ≥2 independent determinations (**7**--**9** were tested three times). The controls were metronidazole (MET), rifampicin (RMP), and isoniazid (INH).

IC~50~ values for cytotoxicity toward VERO cells.

MIC data from ref ([@ref15]).

As expected from our studies in the nitroimidazooxazole class,^[@ref23]^ 3-nitro compounds **7** and **8** were completely inactive in both *M. tb* assays (MICs \> 128 μM; [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). For **8**, this indicates a \>256-fold loss in activity in comparison to its 2-nitro isomer, **4**. Conversely, the 3′-methyl derivative of **4** (**9**) was seven- to eight-fold more active than both **4** and moxifloxacin (**6**) in MABA (similar to rifampicin and bedaquiline **2**) and about three-fold better than both **4** and linezolid (**3**) in LORA (comparable to rifampicin). These results for **9** were in accordance with the findings reported by Cherian et al.^[@ref16]^ for the 3′-methoxy derivative of **4**, which was five-fold superior to **4** in the aerobic assay and two-fold more effective than **4** under hypoxic conditions.

In their original investigation, Kim et al.^[@ref22]^ reported an aerobic MIC~99~ value of 4--8 μM and weak anaerobic activity (MIC~90~ 31 μM) for the compound they believed to be **8** (shown here to be the 2*H*-nitroimidazooxazole **20**). Intriguingly, the same compound also yielded an anaerobic MIC~90~ value of 62.5--125 μM against *M. tb* having mutations in the nitroreductase Ddn, suggesting the participation of a different biological target. While delamanid (**1**) was shown to be primarily triggered by Ddn, several Ddn homologues have been implicated in the cellular activation of simple 2*H*-nitroimidazooxazoles (e.g., 2-Et, 2-Ph).^[@ref34]^ However, in the case of **20**, the lack of significant potency against this Ddn mutant under aerobic conditions (MIC~99~ \> 100 μM) renders this explanation unsatisfactory. Overall, the results of the current investigation support findings from previous studies of resistance to **4**, that the activation of nitroimidazooxazines relies exclusively on Ddn.^[@ref35]^ In this class, relocation of the nitro group from C-2 to C-3 destroys all antitubercular activity, implying that, like the *R*-enantiomer of **4**,^[@ref34]^**8** is not a substrate for Ddn or its homologues and does not release nitric oxide.

In summary, we set out to establish the identities of two novel byproducts from optimization studies around a manufacturing route to **4** through a combination of 2D NMR analysis and *de novo* chiral synthesis. In the case of 3-nitro isomer **8**, this entailed the development of an innovative nitration route, following our discovery of a critical structural assignment error in the published method, and we obtained an X-ray crystal structure of this compound for final confirmation. Preliminary *in vitro* assessments indicated that, whereas the 3′-methyl derivative of **4** (**9**) was markedly more effective than **4**, both **8** and its alcohol precursor **7** were completely inactive, overturning previous misconceptions regarding their aerobic and anaerobic activities and the suggested involvement of another target facilitating their activity against Ddn mutant *M. tb*. These results provide further clarity of fundamental SARs for pretomanid and of the structural features of antitubercular nitroimidazoles that are more likely to overcome any future clinical resistance to **4**.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsmedchemlett.7b00356](http://pubs.acs.org/doi/abs/10.1021/acsmedchemlett.7b00356).Further background, scheme for preparation of racemic **7**, experimental procedures and characterizations for compounds, combustion analytical data, packing diagram for X-ray structure of **8**, crystallographic data, NMR spectra for key compounds, chiral HPLC trace for **7** ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.7b00356/suppl_file/ml7b00356_si_001.pdf))
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